FDA approves Novartis combo therapy for aggressive type of thyroid cancer

FDA approves Novartis combo therapy for aggressive type of thyroid cancer

Submitted by admin on May 4, 2018 - 6:53pm
Source: 
Reuters
News Tags: 
Novartis
FDA
Tafinlar
Mekinist
anaplastic thyroid cancer
Headline: 
FDA approves Novartis combo therapy for aggressive type of thyroid cancer
snippet: 

The U.S. Food and Drug Administration on Friday approved Novartis AG’s combination therapy to treat an aggressive type of thyroid cancer.